Table 1. Cohort characteristics.
| Variables | Groups | ||
|---|---|---|---|
| Score 1 or 2 (n = 23) | Score 3 or 4 (n = 47) | p-value | |
| Age (years), mean (SD) | 57.3 (10.9) | 55.0 (12.4) | 0.434* |
| Sex M:F, n (%) | 1 (4.3): 22 (95.7) | 1 (2.1): 46 (97.9) | 0.600** |
| Disease duration (years), mean (95%CI) | 9.3 (6.5–12.2) | 6.9 (5.2–8.5) | 0.101* |
| ESSDAI, mean (95%CI) | 1.65 (0.81–2.49) | 3.89 (2.77–5.01) | 0.013*** |
| Categorical ESSDAI, n (%) | 0.064** | ||
| ESSDAI < 5 | 20 (87.0) | 31 (66.0) | |
| ESSDAI ≥ 5 | 3 (13.0) | 16 (34.0) | |
| Salivary flow, mean (95%CI) | 0.23 (0.14–0.32) | 0.10 (0.07–0.13) | 0.001*** |
| ANA, n (%) | 0.006** | ||
| Positive | 15 (65.2) | 43 (91.5) | |
| Negative | 8 (34.8) | 4 (8.5) | |
| Anti-Ro/SSA, n (%) | 0.003** | ||
| Positive | 7 (30.4) | 32 (68.1) | |
| Negative | 16 (69.6) | 15 (31.9) | |
| Anti-La/SSB, n (%) | 0.077** | ||
| Positive | 4 (17.4) | 18 (38.3) | |
| Negative | 19 (82.6) | 29 (61.7) | |
| RF, n (%) | 0.034** | ||
| Positive | 8 (34.8) | 29 (61.7) | |
| Negative | 15 (65.2) | 18 (38.3) | |
| IgG, mean (95%CI) | 1268.9 (1083.8–1454.0) | 1543.6 (1363.5–1723.6) | 0.281* |
| Categorical IgG, n (%) | 0.077** | ||
| ≤ 1600 mg/dL | 19 (82.6) | 29 (61.7) | |
| > 1600 mg/dL | 4 (17.4) | 18 (38.3) | |
| Salivary β2M, mean (95%CI) | 3.18 (2.00–4.37) | 3.98 (2.19–5.77) | 0.547*** |
| Serum β2M, mean (95%CI) | 2.27 (0.95–3.59) | 5.73 (2.56–8.89) | 0.088*** |
ANA, antinuclear antibodies; β2M, beta-2 microglobulin; ESSDAI, European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index; IgG, immunoglobulin G; RF, rheumatoid factor.
* Student’s t test
** Chi-square test
*** Mann-Whitney test